| |
| Device | LIAISON XL MUREX Anti-HBc, LIAISON MUREX Control Anti-HBc |
| Generic Name | Qualitative and Quantitative Hepatitis B Virus Antibody assays |
| Regulation Number | 866.3173 |
| Applicant | DiaSorin, Inc. 1951 Northwestern Ave. Stillwater, MN 55082 |
| PMA Number | P180038 |
| Date Received | 09/26/2018 |
| Decision Date | 01/02/2020 |
| Reclassified Date | 10/20/2025 |
| Product Code |
SEI |
| Docket Number | 20M-0107 |
| Notice Date | 01/08/2020 |
| Advisory Committee |
Microbiology |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approval for the LIAISON XL MUREX Anti-HBc assay is an in vitro chemiluminescent immunoassay (CLIA) for the qualitative detection of IgG and IgM (total) antibodies to hepatitis B core antigen (anti-HBc) in human adult and pediatric serum and plasma (lithium and sodium heparin, sodium citrate and K2 EDTA) including separator tubes, on the LIAISON XL Analyzer. Assay results in conjunction with other laboratory results and clinical information may be used as an aid in the diagnosis of hepatitis B virus (HBV) infection in patients with symptoms of hepatitis or who may be at risk for HBV infection. The assay is not intended for use in screening blood, plasma or tissue donors. The LIAISON XL MUREX Control Anti-HBc (negative and positive) is intended for use as assayed quality control samples to monitor the performance of the LIAISON XL MUREX Anti-HBc assay. The performance characteristics of LIAISON XL MUREX Control Anti-HBc have not been established for any other assays or instrument platforms. |
| Approval Order | Approval Order |
| Summary | Summary of Safety and Effectiveness |
| Labeling | Labeling
|
| Supplements: |
S011 S012 S005 S013 S006 S007 S008 S009 S027 S021 S022 S002 S003 S001 S014 S015 S010 S025 S026 S020 S023 S024 S018 S019 S016 S017 |